Combined immunotherapy clinical trials in cancer patients are challenging, and several strategies have been opened for clinical applications. However, the high efficacy of different immunotherapeutic strategies at eliminating tumors in animal models is in contrast with the very limited results achieved in patients. There are many explanations to why immunotherapeutic strategies fail or have little impact on patient survival. In general, for all solid tumors, the common scenario chosen to test immunotherapeutic protocols almost always involves patients with advanced diseases that precludes, or at least decreases, the possibility of success. Then, due to the advanced status of the cancer, the immune system of the majority of treated patients is deteriorated and unable to recognize tumor antigens. Thus, conventional chemotherapy could act in synergy to generate immunity against many tumors. The different forms of immunotherapy including the use of cytokines should be tested for overall clinical benefits along with conventional treatment regimens evidencing improvement in survival.